TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00445120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus Rhamnosus GG
Description: patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (sugar)
Description: Placebo will be administered to patients once daily for six months
Study: NCT01891838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volume controlled ventilation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation
Study: NCT04213638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Single Microneedle Radiofrequency therapy
Description: Subjects are treated with three consecutive sessions of Single Microneedle Radiofrequency therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment. Each treatment session took approximately 30-60 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic therapy
Description: Subjects are treated with three consecutive sessions of Photodynamic therapy at 2-week intervals, with a follow-up visit 12 weeks after the final third treatment.
Study: NCT00775515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic prostatectomy
Description: laparoscopic prostatectomy
Study: NCT00819832

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Description: A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Kyphoplasty
Description: A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Description: Medical cement will be injected into broken back bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Medical cement will be injected into broken back bone.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vertebroplasty
Description: Medical cement will be injected into broken back bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cavity SpineWand
Description: Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cavity SpineWand
Description: Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
Study: NCT02614768

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose Sensor
Description: The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received conformité européenne (CE) certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only.
Study: NCT04066244

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug

Intervention type: DRUG
Group type: OTHER
Intervention: BLZ945
Description: Investigational drug
Study: NCT03275272

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: level of IGF-1 in infants
Description: Measurment of blood level of IGF-1 in infants
Study: NCT00901095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
Study: NCT04174820

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests

Intervention type: OTHER
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: list of the tests: Box and Blocks test, Nine Hole Peg test, walkway GAITRite, EXALang tests, NEPSY II subtests, BRIEF, FEE, WISC 5 tests
Study: NCT02261532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study: NCT03335267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: Cytarabine:Daunorubicin Liposome Injection
Study: NCT01497093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 20 mg/day \[≤ 75 years old\] or 10 mg/day \[\> 75 years old\] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
Study: NCT01163500

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: coenzyme Q10 supplements 60 mg/day and 150 mg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled (dextrin)
Study: NCT01646216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Split belt treadmill
Description: A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
Study: NCT03767894

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG Band
Description: The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear an EMG band to control and activate the MyHand orthosis.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder harness
Description: The MyHand orthosis provides tension to the digits to open the fingers on demand. This group will wear a shoulder strap to control and activate the MyHand orthosis, either with shoulder elevation or shoulder depression.
Study: NCT03749863

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial PRP injections
Description: Autologous platelet-rich plasma will be injected into the vocal fold mucosa in a serial fashion, once per month for a total of 4 injections.
Study: NCT02882516

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
Study: NCT00576342

Intervention type: DRUG
Group type: OTHER
Intervention: AL-3862+timolol ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: AL-3862+timolol ophthalmic suspension

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide+timolol ophthalmic solution

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzolamide+timolol ophthalmic solution
Study: NCT00834587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5 mg/500 mg METAGLIP™ Tablets
Description: 1 x 5 mg/500 mg, single-dose non-fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg/500 mg Glipizide Metformin Hydrochloride Tablets
Description: 1 x 5 mg/500 mg, single-dose non-fasting
Study: NCT01297114

Intervention type: DRUG
Intervention: Florbetaben
Description: This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
Study: NCT02540434

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM
Description: ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROTEM
Description: ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cryoprecipitate
Description: Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RiaSTAP
Description: Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
Study: NCT01264627

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Breathing (MB) Intervention
Description: The Mindful Breathing (MB)intervention is based on MBSR developed by Jon Kabat-Zinn. Participants will attend 8 individual weekly MB sessions. MB consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, from a non-evaluative or judgmental perspective. As attention wanders to concerns or thoughts, participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the 8 training sessions with a breathing monitor.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care (UC) Control Condition
Description: This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and (Blood Pressure) BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources.
Study: NCT04589715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: the same as described in experimental arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham electroacupuncture
Description: the same as described in sham comparator.
Study: NCT02825407

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral physiology
Study: NCT00827671

Intervention type: DRUG
Group type: OTHER
Intervention: cetuximab
Description: cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment

Intervention type: RADIATION
Group type: OTHER
Intervention: radiotherapy to oesophageal tumour
Description: 45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
Study: NCT00794027

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga Classes
Description: 8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga classes
Description: Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
Study: NCT00564720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100 mg by mouth (p.o.), daily until disease progression
Study: NCT03702933

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-serine
Description: dosage

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-serine
Description: dosage

Intervention type: DIETARY_SUPPLEMENT
Intervention: D-serine
Description: dosage
Study: NCT06626607

Intervention type: DRUG
Intervention: CCB use
Description: Postoperative antihypertensive medication includes CCB

Intervention type: DRUG
Intervention: non-CCB use
Description: Postoperative antihypertensive medication does not include CCB
Study: NCT03402763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: The intervention is an educational video presented to patients in the ED with the intent to promote ACP among older adults.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Provider Email
Description: For intervention patients, an email will be sent to primary care providers explaining that the patient has seen a video about advance care planning, providing a synopsis of the video, and giving instructions about how to document end-of-life care preferences in the electronic health record.
Study: NCT01902160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT00564720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 100 mg by mouth (p.o.), daily until disease progression
Study: NCT03366415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine and cisplatin (Induction and adjuvant chemotherapy)
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before IMRT and after IMRT.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4 Gy to the primary tumor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine and cisplatin (Induction chemotherapy)
Description: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (25mg/m² d1-3) every 3 weeks for 2 cycles before concurrent chemoradiotherapy.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT and concurrent cisplatin
Description: Intensity modulated-radiotherapy (IMRT) is given as 2.2 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 or 70.4Gy to the primary tumor, concurrently with cisplatin 30mg/m² every week.
Study: NCT02845180

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Allograft Extracellular Matrix (AAM) Injection
Description: Injection followed by surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adipose Allograft Extracellular Matrix (AAM) Injection
Description: Injection followed by surgery
Study: NCT02787798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valsartan/sacubitril 100 mg
Description: Treatment with 100 mg tablets during 2 to 4 weeks
Study: NCT02102230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: This is a group-delivered version of the six-session Cognitive-Behavioral Treatment for Insomnia that has been disseminated throughout the VA. It incorporates psychoeducation, diary-based sleep assessment, estimation of sleep scheduling and efficiency, evaluation/mitigation of dysfunctional sleep-related beliefs/ behaviors, generation of sleep prescription (typically restriction), iterative review of sleep efficiency and prescription, and planning for maintenance of gains.
Study: NCT00564720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
Study: NCT01919840

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group ROTEM
Description: 10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.~If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: 10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.~If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result.
Study: NCT00976508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: figitumumab
Description: IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegvisomant
Description: growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
Study: NCT03088462

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric management
Description: Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychiatric management
Description: Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosocial treatment
Description: Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.